Website
News25/Ratings2
News · 26 weeks21+100%
2025-10-262026-04-19
Mix690d
- SEC Filings3(50%)
- Market2(33%)
- Other1(17%)
Latest news
25 items- SECAytu BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Aytu BioPharma Inc.SCHEDULE 13G/A - AYTU BIOPHARMA, INC (0001385818) (Subject)
- SECSEC Form 10-Q filed by Aytu BioPharma Inc.10-Q - AYTU BIOPHARMA, INC (0001385818) (Filer)
- SECAytu BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
- NEWSAytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial ResultsTotal net revenue of $15.2 millionAdjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments$30.0 million cash balance at December 31, 2025Company launched EXXUA™ (gepirone) extended-release tablets ("EXXUA") in December 2025 as the centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") marketCompany to host conference call and webcast today, February 3, 2026, at 4:30 p.m. Eastern timeDENVER, CO / ACCESS Newswire / February 3, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system dis
- NEWSAytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026DENVER, CO / ACCESS Newswire / January 27, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its second quarter of fiscal 2026, after the market close on Tuesday, February 3, 2026. The Company has scheduled a conference call and webcast that same day, Tuesday, February 3, 2026, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.Conference Call DetailsDate and Time: Tuesday, February 3, 2026, at 4:30 p.m. Eastern time.Call-in In
- SECAytu BioPharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
- NEWSAytu BioPharma Recaps Investor Day Held on January 20, 2026DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today provided a summary of the Company's Investor Day, held today, Tuesday, January 20, 2026, at 11:00 a.m. Eastern time in New York City. The Investor Day was conducted both in-person and via webcast.A replay of the event can be found on the Investors section of the Company's website at https://investors.aytubio.com under Events & Presentations. The event can also be accessed directly at https://app.webinar.net/Qo7DrDvVzq8.The
- NEWSAytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUAEXXUA addresses frequent causes of treatment discontinuation with first-line SSRIs and SNRIsNow commercially available through retail pharmacies and participating Aytu RxConnect® pharmacies to support patient accessDENVER, COLORADO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines to treat complex central nervous system disorders and improve the quality of life of patients, today announced the nationwide commercial launch of EXXUA and successful completion of its launch meeting last week that finalized sales training and launch preparations for EXXUA, the first and only selec
- NEWSAytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026DENVER, CO / ACCESS Newswire / January 13, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, announced today that Josh Disbrow, Chief Executive Officer of Aytu, will participate in a fireside chat moderated by Thomas Flaten, Senior Research Analyst at Lake Street Capital Markets, at the Lytham Partners 2026 Investor Healthcare Summit.The webcast will take place at 5:00 p.m. Eastern time on Thursday, January 15, 2026. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/hc2026/ o
- NEWSAytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York CityDENVER, CO / ACCESS Newswire / January 12, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today provided additional details for its upcoming Investor Day, scheduled for Tuesday, January 20, 2026, at 11:00 a.m. Eastern time in New York City. The Investor Day will be both in-person and available to view via webcast.In-Person InformationConvene Conference Center530 Fifth AvenueNew York, NY 10036Advance registration is required for in-person attendance. Please contact Aytu's Investor Relations at aytu@lythampartners.com
- NEWSAytu BioPharma to Host Investor Day on January 20, 2026 in New York CityDENVER, CO / ACCESS Newswire / December 18, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will be hosting an Investor Day on Tuesday, January 20, 2026, at 11:00 a.m. Eastern time in New York City.The Investor Day will include presentations from Aytu's senior leadership and discussions with Key Opinion Leaders ("KOLs") regarding the EXXUA™ (gepirone) extended-release tablets ("EXXUA") opportunity, followed by a live Q&A session. EXXUA is the first and only 5HT1a agonist approved by the United States Food and Drug Adm
- NEWSAytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in AdultsEXXUA is now available through Aytu RxConnect® pharmacies to ensure optimal access and availabilityEXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, has no warnings or adverse events related to sexual dysfunction and no clinically significant weight gain compared to placeboDENVER, CO / ACCESS Newswire / December 15, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced the commercial availability of EXXUA in the United St
- SECAytu BioPharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
- NEWSAytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity ConferenceDENVER, CO / ACCESS Newswire / November 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that its management will participate at NobleCon21 - Noble Capital Markets' 21st Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL.Management will be presenting on Wednesday, December 3rd at 10:30 a.m. Eastern time. A high-definition video webcast of the presentation will be available the following day on the Company's website (www.aytubio.com
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Aytu BioPharma Inc.SCHEDULE 13G/A - AYTU BIOPHARMA, INC (0001385818) (Subject)
- SECSEC Form 10-Q filed by Aytu BioPharma Inc.10-Q - AYTU BIOPHARMA, INC (0001385818) (Filer)
- SECAytu BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
- NEWSAytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial ResultsTotal net revenue of $13.9 millionNet income of $2.0 million, or $0.21 net income per share basicAdjusted EBITDA1 of $(0.6) million, which includes EXXUA launch investments$32.6 million cash balance at September 30, 2025Company remains on track to launch EXXUA™ (gepirone) extended-release tablets ("EXXUA") in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") marketCompany to host conference call and webcast today, November 13, 2025, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / November 13, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU),
- NEWSAytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025DENVER, CO / ACCESS Newswire / November 5, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its first quarter of fiscal 2026, after the market close on Thursday, November 13, 2025. The Company has scheduled a conference call and webcast that same day, Thursday, November 13, 2025, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.Conference Call DetailsDate and Time: Thursday, November 13, 2025, at 4:30 p.m. Eastern time.Call-
- NEWSAytu BioPharma Announces Patent Term Extension for EXXUA(TM)DENVER, CO / ACCESS Newswire / October 28, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that the method of use patent (U.S. Patent No. 7,538,116) for EXXUATM (gepirone) extended-release tablets ("EXXUA") has been extended through September 2, 2030 under 35 U.S.C. 156. The patent extension further expands upon the new chemical entity ("NCE") exclusivity period granted by the United States Food and Drug Administration ("FDA"). Gepirone is an NCE, and EXXUA is the first-in-class selective serotonin 5HT
- SECSEC Form DEFA14A filed by Aytu BioPharma Inc.DEFA14A - AYTU BIOPHARMA, INC (0001385818) (Filer)
- SECSEC Form DEF 14A filed by Aytu BioPharma Inc.DEF 14A - AYTU BIOPHARMA, INC (0001385818) (Filer)
- INSIDERDockery Carl bought $9,230 worth of shares (10,000 units at $0.92) and sold $1,256 worth of shares (209 units at $6.01) (SEC Form 5)5 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
- NEWSAytu BioPharma to Present at Upcoming October 2025 ConferencesDENVER, CO / ACCESS Newswire / October 10, 2025 / DENVER, CO / ACCESS Newswire / October 10, 2025 /Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced management will participate at the following investor conferences:2025 Maxim Growth SummitDate: October 22, 2025Location: New York CityInvestors should reach out to their Maxim sales representatives, or Robert Blum of Lytham Partners at aytu@lythampartners.com to schedule one-on-one meetings with Aytu's management.Planet MicroCap Showcase: TORONTO 2025Date: October